Results 201 to 210 of about 9,522 (255)
Some of the next articles are maybe not open access.
European journal of pharmaceutics and biopharmaceutics, 2022
Alopecia is a condition associated with different etiologies, ranging from hormonal changes to chemotherapy, that affects over 80 million people in the USA.
Paula M. Oliveira +6 more
semanticscholar +1 more source
Alopecia is a condition associated with different etiologies, ranging from hormonal changes to chemotherapy, that affects over 80 million people in the USA.
Paula M. Oliveira +6 more
semanticscholar +1 more source
Dermatologic Therapy, 2022
Alopecia areata (AA) is a recurrent chronic disease that affects hair follicles and results in hair loss. Make an increase in the number, thickness, and length of eyelashes is an important side effect of latanoprost eye drop. This study aimed to evaluate
M. Rafati +5 more
semanticscholar +1 more source
Alopecia areata (AA) is a recurrent chronic disease that affects hair follicles and results in hair loss. Make an increase in the number, thickness, and length of eyelashes is an important side effect of latanoprost eye drop. This study aimed to evaluate
M. Rafati +5 more
semanticscholar +1 more source
Neuroprotective properties of latanoprost
Vestnik oftal'mologii, 2022Glaucoma is the main cause of irreversible blindness in the world. Latanoprost - an ester prodrug of prostaglandin F2α (PGF2α) - was the first prostaglandin analogue used to treat glaucoma. The review shows that latanoprost possesses direct neuroprotective properties such as blocking the entry of calcium ions into neurons and inhibiting the action of ...
openaire +2 more sources
Japanese Journal of Ophthalmology, 2004
Latanoprost is a prostaglandin analogue with well-established efficacy in the treatment of open-angle glaucoma and ocular hypertension. Once-daily administration of this drug for up to 5 years is generally well tolerated both locally and systemically.
Ian Grierson +2 more
openaire +3 more sources
Latanoprost is a prostaglandin analogue with well-established efficacy in the treatment of open-angle glaucoma and ocular hypertension. Once-daily administration of this drug for up to 5 years is generally well tolerated both locally and systemically.
Ian Grierson +2 more
openaire +3 more sources
Latanoprost exposure in pregnancy
American Journal of Ophthalmology, 2004To observe pregnancies exposed to latanoprost, a prostaglandin analog administered in the treatment of glaucoma. Its prescription is limited in pregnancy, because reproduction studies in animals report a high incidence of abortion and human investigations are not adequate.
De Santis, Marco +7 more
openaire +4 more sources
Journal of Cataract and Refractive Surgery, 1999
link_to_subscribed_fulltext
Chua, JKH, Lai, JSM, Lam, DSC
openaire +5 more sources
link_to_subscribed_fulltext
Chua, JKH, Lai, JSM, Lam, DSC
openaire +5 more sources
Seminars in Ophthalmology, 1997
Latanoprost is a new topical ocular prostaglandin that decreases intraocular pressure (IOP) by increasing uveoscleral outflow. Its efficacy is comparable with that of timolol and it shows almost complete additivity with timolol. Once daily dosing of 0.005% latanoprost yields a maximal effect with no significant circadian fluctuation in IOP.
Theodore Krupin +4 more
openaire +2 more sources
Latanoprost is a new topical ocular prostaglandin that decreases intraocular pressure (IOP) by increasing uveoscleral outflow. Its efficacy is comparable with that of timolol and it shows almost complete additivity with timolol. Once daily dosing of 0.005% latanoprost yields a maximal effect with no significant circadian fluctuation in IOP.
Theodore Krupin +4 more
openaire +2 more sources
Journal of Ocular Pharmacology and Therapeutics, 2021
Purpose: To investigate the influence of benzalkonium chloride (BAK) on ocular surface disease (OSD) in glaucoma patients receiving ocular-hypotensive agent.
Jo-Hsuan Wu +3 more
semanticscholar +1 more source
Purpose: To investigate the influence of benzalkonium chloride (BAK) on ocular surface disease (OSD) in glaucoma patients receiving ocular-hypotensive agent.
Jo-Hsuan Wu +3 more
semanticscholar +1 more source